1. Academic Validation
  2. Discovery of Novel 1-Phenylpiperidine Urea-Containing Derivatives Inhibiting β-Catenin/BCL9 Interaction and Exerting Antitumor Efficacy through the Activation of Antigen Presentation of cDC1 Cells

Discovery of Novel 1-Phenylpiperidine Urea-Containing Derivatives Inhibiting β-Catenin/BCL9 Interaction and Exerting Antitumor Efficacy through the Activation of Antigen Presentation of cDC1 Cells

  • J Med Chem. 2024 Jun 24. doi: 10.1021/acs.jmedchem.3c02079.
Wenhua Zhu 1 2 Cuiting Liu 1 2 Kang Xi 1 2 Anqi Li 3 Li-An Shen 3 Yana Li 1 2 Miaomiao Jia 1 2 Yangbo He 1 2 Gang Chen 1 2 Chenglong Liu 3 Yangqiang Chen 1 2 Kai Chen 4 Fan Sun 4 Daizhou Zhang 5 Chonggang Duan 5 Heng Wang 3 Dongdong Wang 6 Yujun Zhao 7 Xiangjing Meng 5 Di Zhu 3
Affiliations

Affiliations

  • 1 Anhui University of Chinese Medicine, Hefei 230012, China.
  • 2 Yangtze Delta Drug Advanced Research Institute and Yangtze Delta Pharmaceutical College, Nantong 226133, China.
  • 3 School of Basic Medical Sciences, Fudan University, Shanghai 201210, China.
  • 4 Shanghai Jiao Tong University, Shanghai 201210, China.
  • 5 Shandong Academy of Pharmaceutical Science, Jinan 250101, China.
  • 6 DP Technology, Beijing 100080, China.
  • 7 State Key Laboratory of Drug Research and Small-Molecule Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Rd., Shanghai 201203, China.
Abstract

Aberrant activation of the Wnt/β-catenin signaling is associated with tumor development, and blocking β-catenin/BCL9 is a novel strategy for oncogenic Wnt/β-catenin signaling. Herein, we presented two novel β-catenin variations and exposed conformational dynamics in several β-catenin crystal structures at the BCL9 binding site. Furthermore, we identified a class of novel urea-containing compounds targeting β-catenin/BCL9 interaction. Notably, the binding modalities of inhibitors were greatly affected by the conformational dynamics of β-catenin. Among them, 28 had a strong affinity for β-catenin (Kd = 82 nM), the most potent inhibitor reported. In addition, 13 and 35 not only activate T cells but also promote the antigen presentation of cDC1, showing robust antitumor efficacy in the CT26 model. Collectively, our study demonstrated a series of potent small-molecule inhibitors targeting β-catenin/BCL9, which can enhance antigen presentation and activate cDC1 cells, delivering a potential strategy for boosting innate and adaptive immunity to overcome immunotherapy resistance.

Figures
Products
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》